Related references
Note: Only part of the references are listed.Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from BrighTNess, a randomized phase III trial
C. E. Geyer et al.
ANNALS OF ONCOLOGY (2022)
Effect of Capecitabine Maintenance Therapy Using Lower Dosage and Higher Frequency vs Observation on Disease-Free Survival Among Patients With Early-Stage Triple-Negative Breast Cancer Who Had Received Standard Treatment The SYSUCC-001 Randomized Clinical Trial
Xi Wang et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)
Prognostic Impact of Ki-67 Change in Locally Advanced and Early Breast Cancer after Neoadjuvant Chemotherapy: A Single Institution Experience
Mirco Pistelli et al.
JOURNAL OF ONCOLOGY (2021)
Neoadjuvant Therapy of Cyclin-Dependent Kinase 4/6 Inhibitors Combined with Endocrine Therapy in HR+/HER2-Breast Cancer: A Systematic Review and Meta-Analysis
Kai Hong et al.
ONCOLOGY RESEARCH AND TREATMENT (2021)
Capecitabine Can Induce T Cell Apoptosis: A Potential Immunosuppressive Agent With Anti-Cancer Effect
Sai Zhang et al.
FRONTIERS IN IMMUNOLOGY (2021)
Phase III Trial of Adjuvant Capecitabine After Standard Neo-/Adjuvant Chemotherapy in Patients With Early Triple-Negative Breast Cancer (GEICAM/2003-11_CIBOMA/2004-01)
Ana Lluch et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Pembrolizumab for Early Triple-Negative Breast Cancer
Peter Schmid et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Adjuvant Capecitabine With Docetaxel and Cyclophosphamide Plus Epirubicin for Triple-Negative Breast Cancer (CBCSG010): An Open-Label, Randomized, Multicenter, Phase III Trial
Junjie Li et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
PARP Inhibitors in the Treatment of Early Breast Cancer: The Step Beyond?
Anthony Goncalves et al.
CANCERS (2020)
West German Study PlanB Trial: Adjuvant Four Cycles of Epirubicin and Cyclophosphamide Plus Docetaxel Versus Six Cycles of Docetaxel and Cyclophosphamide in HER2-Negative Early Breast Cancer
Ulrike Nitz et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Randomized Trial of Standard Adjuvant Chemotherapy Regimens Versus Capecitabine in Older Women With Early Breast Cancer: 10-Year Update of the CALGB 49907 Trial
Hyman B. Muss et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Assessment of the predictive role of pretreatment Ki-67 and Ki-67 changes in breast cancer patients receiving neoadjuvant chemotherapy according to the molecular classification: a retrospective study of 1010 patients
Rui Chen et al.
BREAST CANCER RESEARCH AND TREATMENT (2018)
Efficacy and safety of low-dose capecitabine plus docetaxel versus single-agent docetaxel in patients with anthracycline-pretreated HER2-negative metastatic breast cancer: results from the randomized phase III JO21095 trial
Daigo Yamamoto et al.
BREAST CANCER RESEARCH AND TREATMENT (2017)
Capecitabine in early breast cancer: A meta-analysis of randomised controlled trials
Akina Natori et al.
EUROPEAN JOURNAL OF CANCER (2017)
Ki-67 labeling index is a predictive marker for a pathological complete response to neoadjuvant chemotherapy in breast cancer: A meta-analysis
Miaomiao Tao et al.
MEDICINE (2017)
Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy
N. Masuda et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Adjuvant Capecitabine in Combination With Docetaxel, Epirubicin, and Cyclophosphamide for Early Breast Cancer The Randomized Clinical FinXX Trial
Heikki Joensuu et al.
JAMA ONCOLOGY (2017)
Patients with Slowly Proliferative Early Breast Cancer Have Low Five-Year Recurrence Rates in a Phase III Adjuvant Trial of Capecitabine
Joyce O'Shaughnessy et al.
CLINICAL CANCER RESEARCH (2015)
Survival after adding capecitabine and trastuzumab to neoadjuvant anthracycline-taxane-based chemotherapy for primary breast cancer (GBG 40-GeparQuattro)
G. von Minckwitz et al.
ANNALS OF ONCOLOGY (2014)
Clinical Efficacy of Including Capecitabine in Neoadjuvant Chemotherapy for Breast Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
Qiuyun Li et al.
PLOS ONE (2013)
Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials
K. Albain et al.
LANCET (2012)
Thymidine phosphorylase expression and benefit from capecitabine in patients with advanced breast cancer
C. Andreetta et al.
ANNALS OF ONCOLOGY (2009)
The prognostic significance of Ki67 before and after neoadjuvant chemotherapy in breast cancer
Robin L. Jones et al.
BREAST CANCER RESEARCH AND TREATMENT (2009)
Phase III Study of Gemcitabine Plus Docetaxel Compared With Capecitabine Plus Docetaxel for Anthracycline-Pretreated Patients With Metastatic Breast Cancer
Stephen Chan et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Docetaxel With Cyclophosphamide Is Associated With an Overall Survival Benefit Compared With Doxorubicin and Cyclophosphamide: 7-Year Follow-Up of US Oncology Research Trial 9735
Stephen Jones et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
A randomized phase-III trial of docetaxel/capecitabine versus doxorubicin/cyclophosphamide as primary chemotherapy for patients with stage II/III breast cancer
Keun Seok Lee et al.
BREAST CANCER RESEARCH AND TREATMENT (2008)
Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival:: an overview of the randomised trials
O Abe et al.
LANCET (2005)
Breast cancer molecular subtypes respond differently to preoperative chemotherapy
R Rouzier et al.
CLINICAL CANCER RESEARCH (2005)
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival:: an overview of the randomised trials
O Abe et al.
LANCET (2005)
Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: Phase III trial results
J O'Shaughnessy et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Correlation of thymidine phosphorylase staining and the Ki-67 labeling index to clinicopathologic factors and hepatic metastasis in patients with colorectal cancer
T Kitabatake et al.
SURGERY TODAY (2002)
Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognostic factors:: 5-year follow-up results of French adjuvant study group 05 randomized trial
A Adenis et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Clinical pharmacokinetics of capecitabine
B Reigner et al.
CLINICAL PHARMACOKINETICS (2001)
Capecitabine: preclinical pharmacology studies
H Ishitsuka
INVESTIGATIONAL NEW DRUGS (2000)
Molecular portraits of human breast tumours
CM Perou et al.
NATURE (2000)
Share Paper
